% Exported from Psilocybin Research Publication Tracker
% Tracker site: https://psilocybin-research.com
% Publication tracker: https://psilocybin-research.com/
\documentclass[11pt]{article}
\usepackage[T1]{fontenc}
\usepackage[utf8]{inputenc}
\usepackage{enumitem}
\usepackage[hidelinks]{hyperref}
\usepackage[margin=1in]{geometry}
\title{Psilocybin and Psilocin Research Export}
\author{Psilocybin Research Publication Tracker}
\date{2026-07-05}
\begin{document}
\maketitle
\noindent Exported from \href{https://psilocybin-research.com}{psilocybin-research.com}. Records: 51.

\begin{enumerate}[leftmargin=*]
\item Urban MM, Zillich L, Rieser NM, Herdener M, Spanagel R, Vollenweider FX, Preller KH, Meinhardt MW. (2026). \textit{Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41398-026-03961-3}{doi:10.1038/s41398-026-03961-3}.
\item Allohverdi SG, Soltanzadeh M, Schmidt A, Charlton CE, Hauke DJ, Karvelis P, Vollenweider FX, Diaconescu AO. (2025). \textit{Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.11.06.687023}{doi:10.1101/2025.11.06.687023}.
\item Urban MM, Zillich L, Rieser NM, Herdener M, Vollenweider FX, Spanagel R, Preller KH, Meinhardt MW. (2025). \textit{Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.07.18.664368}{doi:10.1101/2025.07.18.664368}.
\item Yaden DB, Graziosi M, Owen AM, Agin-Liebes G, Aaronson ST, Allen KE, Barrett FS, Bogenschutz MP, Carhart-Harris R, Ching THW, Cosimano MP, Danforth A, Davis AK, Garcia-Romeu A, Griffiths R, Grob CS, Gründer G, Gukasyan N, Heinzerling KG, Hendricks PS, Holze F, Horton DM, Johnson MW, Kelmendi B, Knatz Peck S, Koslowski M, Liechti ME, Mertens LJ, Moreno FA, Nayak SM, Nicholas CR, Preller KH, Rieser NM, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk DS, Vollenweider FX, Weiss B, Wolff M, Yaden ME. (2025). \textit{A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/psymed.2024.0019}{doi:10.1089/psymed.2024.0019}.
\item Singer B, Meling D, Hirsch-Hoffmann M, Michels L, Kometer M, Smigielski L, Dornbierer D, Seifritz E, Vollenweider FX, Scheidegger M. (2024). \textit{Author Correction: Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41598-024-59897-5}{doi:10.1038/s41598-024-59897-5}.
\item von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX. (2023). \textit{Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.eclinm.2023.101841}{doi:10.1016/j.eclinm.2023.101841}.
\item Stoliker D, Preller KH, Novelli L, Anticevic A, Egan GF, Vollenweider FX, Razi A. (2022). \textit{Neural mechanisms of psychedelic visual imagery}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.09.07.22279700}{doi:10.1101/2022.09.07.22279700}.
\item Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A. (2022). \textit{Effective connectivity of emotion and cognition under psilocybin}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.09.06.22279626}{doi:10.1101/2022.09.06.22279626}.
\item Duerler P, Brem S, Fraga-González G, Neef T, Allen M, Zeidman P, Stämpfli P, Vollenweider FX, Preller KH. (2021). \textit{Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study.}. Cerebral Cortex. [published; Europe PMC]. \href{https://doi.org/10.1093/cercor/bhab202}{doi:10.1093/cercor/bhab202}.
\item Grandjean J, Buehlmann D, Buerge M, Sigrist H, Seifritz E, Vollenweider FX, Pryce CR, Rudin M. (2019). \textit{Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/751255}{doi:10.1101/751255}.
\item Grimm O, Kraehenmann R, Preller KH, Seifritz E, Vollenweider FX. (2018). \textit{Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.}. European Neuropsychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1016/j.euroneuro.2018.03.016}{doi:10.1016/j.euroneuro.2018.03.016}.
\item Kometer M, Vollenweider FX. (2017). \textit{Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2016\_461}{doi:10.1007/7854\_2016\_461}.
\item Preller KH, Vollenweider FX (2017). \textit{Phenomenology, Structure, and Dynamic of Psychedelic States.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2016\_459}{doi:10.1007/7854\_2016\_459}.
\item Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. (2017). \textit{LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.}. Frontiers in Pharmacology. [published; Europe PMC]. \href{https://doi.org/10.3389/fphar.2017.00814}{doi:10.3389/fphar.2017.00814}.
\item Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX. (2017). \textit{Effect of Psilocybin on Empathy and Moral Decision-Making.}. The International Journal of Neuropsychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1093/ijnp/pyx047}{doi:10.1093/ijnp/pyx047}.
\item Lewis CR, Preller KH, Kraehenmann R, Michels L, Staempfli P, Vollenweider FX. (2017). \textit{Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.}. NeuroImage. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuroimage.2017.07.020}{doi:10.1016/j.neuroimage.2017.07.020}.
\item Preller KH, Pokorny T, Hock A, Kraehenmann R, Stämpfli P, Seifritz E, Scheidegger M, Vollenweider FX. (2016). \textit{Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.}. Proceedings of the National Academy of Sciences. [published; Europe PMC]. \href{https://doi.org/10.1073/pnas.1524187113}{doi:10.1073/pnas.1524187113}.
\item Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. (2016). \textit{Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.}. European Neuropsychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1016/j.euroneuro.2016.01.005}{doi:10.1016/j.euroneuro.2016.01.005}.
\item Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX. (2015). \textit{The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.}. NeuroImage Clinical. [published; Europe PMC]. \href{https://doi.org/10.1016/j.nicl.2015.08.009}{doi:10.1016/j.nicl.2015.08.009}.
\item Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. (2014). \textit{Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.}. Biological Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1016/j.biopsych.2014.04.010}{doi:10.1016/j.biopsych.2014.04.010}.
\item Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX. (2013). \textit{Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.}. Cerebral Cortex. [published; Europe PMC]. \href{https://doi.org/10.1093/cercor/bht178}{doi:10.1093/cercor/bht178}.
\item Kometer M, Schmidt A, Jäncke L, Vollenweider FX. (2013). \textit{Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.}. Journal of Neuroscience. [published; Europe PMC]. \href{https://doi.org/10.1523/jneurosci.3007-12.2013}{doi:10.1523/jneurosci.3007-12.2013}.
\item Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. (2012). \textit{Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.}. Biological Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1016/j.biopsych.2012.04.005}{doi:10.1016/j.biopsych.2012.04.005}.
\item Studerus E, Gamma A, Kometer M, Vollenweider FX. (2012). \textit{Prediction of psilocybin response in healthy volunteers.}. PLoS ONE. [published; Europe PMC]. \href{https://doi.org/10.1371/journal.pone.0030800}{doi:10.1371/journal.pone.0030800}.
\item Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX. (2011). \textit{Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/npp.2011.261}{doi:10.1038/npp.2011.261}.
\item Quednow BB, Kometer M, Geyer MA, Vollenweider FX. (2011). \textit{Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.}. Neuropsychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1038/npp.2011.228}{doi:10.1038/npp.2011.228}.
\item Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX. (2010). \textit{The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.}. Biological Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1016/j.biopsych.2010.10.002}{doi:10.1016/j.biopsych.2010.10.002}.
\item Studerus E, Kometer M, Hasler F, Vollenweider FX. (2010). \textit{Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881110382466}{doi:10.1177/0269881110382466}.
\item Studerus E, Gamma A, Vollenweider FX. (2010). \textit{Psychometric evaluation of the altered states of consciousness rating scale (OAV).}. PLoS ONE. [published; Europe PMC]. \href{https://doi.org/10.1371/journal.pone.0012412}{doi:10.1371/journal.pone.0012412}.
\item Vollenweider FX, Kometer M. (2010). \textit{The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/nrn2884}{doi:10.1038/nrn2884}.
\item Hasler F, Kuznetsova OF, Krasikova RN, Cservenyak T, Quednow BB, Vollenweider FX, Ametamey SM, Westera G. (2008). \textit{GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.apradiso.2008.12.007}{doi:10.1016/j.apradiso.2008.12.007}.
\item Geyer MA, Vollenweider FX. (2008). \textit{Serotonin research: contributions to understanding psychoses.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.tips.2008.06.006}{doi:10.1016/j.tips.2008.06.006}.
\item Wackermann J, Wittmann M, Hasler F, Vollenweider FX. (2008). \textit{Effects of varied doses of psilocybin on time interval reproduction in human subjects.}. Neuroscience Letters. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neulet.2008.02.006}{doi:10.1016/j.neulet.2008.02.006}.
\item Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX. (2007). \textit{Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.}. Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-007-0930-9}{doi:10.1007/s00213-007-0930-9}.
\item Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. (2007). \textit{The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval.}. Neuropsychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1038/sj.npp.1301324}{doi:10.1038/sj.npp.1301324}.
\item Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX. (2006). \textit{Effects of psilocybin on time perception and temporal control of behaviour in humans.}. Queensland's institutional digital repository (The University of Queensland). [published; Europe PMC]. \href{https://doi.org/10.1177/0269881106065859}{source link}.
\item Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. (2005). \textit{Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.}. Journal of Cognitive Neuroscience. [published; Europe PMC]. \href{https://doi.org/10.1162/089892905774597191}{doi:10.1162/089892905774597191}.
\item Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX. (2005). \textit{Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/sj.npp.1300621}{doi:10.1038/sj.npp.1300621}.
\item Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. (2004). \textit{Psilocybin impairs high-level but not low-level motion perception.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/00001756-200408260-00023}{doi:10.1097/00001756-200408260-00023}.
\item Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. (2003). \textit{Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-003-1640-6}{doi:10.1007/s00213-003-1640-6}.
\item Vollenweider FX, Vollenweider-Scherpenhuyzen MF. (2003). \textit{[Hallucinogens, amphetamines and entactogens].}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1024/0040-5930.60.6.323}{doi:10.1024/0040-5930.60.6.323}.
\item Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T, Koller R. (2002). \textit{Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/sj.npp.1300005}{doi:10.1038/sj.npp.1300005}.
\item Hasler F, Bourquin D, Brenneisen R, Vollenweider FX. (2002). \textit{Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/s0731-7085(02)00278-9}{doi:10.1016/s0731-7085(02)00278-9}.
\item Umbricht D, Koller R, Vollenweider FX, Schmid L. (2002). \textit{Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/s0006-3223(01)01242-2}{doi:10.1016/s0006-3223(01)01242-2}.
\item Vollenweider FX. (2001). \textit{Brain mechanisms of hallucinogens and entactogens.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.31887/dcns.2001.3.4/fxvollenweider}{doi:10.31887/dcns.2001.3.4/fxvollenweider}.
\item Vollenweider FX, Geyer MA. (2001). \textit{A systems model of altered consciousness: integrating natural and drug-induced psychoses.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/s0361-9230(01)00646-3}{doi:10.1016/s0361-9230(01)00646-3}.
\item Vollenweider FX, Vontobel P, Hell D, Leenders KL. (1999). \textit{5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/s0893-133x(98)00108-0}{doi:10.1016/s0893-133x(98)00108-0}.
\item Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. (1998). \textit{Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/00001756-199812010-00024}{doi:10.1097/00001756-199812010-00024}.
\item Vollenweider FX. (1998). \textit{Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1055/s-2007-979353}{doi:10.1055/s-2007-979353}.
\item Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX. (1997). \textit{Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/s0031-6865(97)00014-9}{doi:10.1016/s0031-6865(97)00014-9}.
\item Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. (1997). \textit{Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/s0893-133x(96)00246-1}{doi:10.1016/s0893-133x(96)00246-1}.
\end{enumerate}
\end{document}
